INT121471

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.34
First Reported 2004
Last Reported 2008
Negated 0
Speculated 1
Reported most in Body
Documents 24
Total Number 26
Disease Relevance 13.79
Pain Relevance 4.73

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Pde3a) signal transduction (Pde3a)
Anatomy Link Frequency
immune system 1
Pde3a (Mus musculus)
Pain Link Frequency Relevance Heat
Inflammation 880 99.66 Very High Very High Very High
agonist 24 98.96 Very High Very High Very High
Restless leg syndrome 22 98.60 Very High Very High Very High
Potency 44 90.88 High High
isoflurane 6 78.48 Quite High
anesthesia 4 77.28 Quite High
dexamethasone 264 67.52 Quite High
cytokine 176 56.20 Quite High
chemokine 22 47.12 Quite Low
Inflammatory mediators 22 20.32 Low Low
Disease Link Frequency Relevance Heat
INFLAMMATION 902 99.66 Very High Very High Very High
Asthma 286 99.44 Very High Very High Very High
Increased Venous Pressure Under Development 22 98.60 Very High Very High Very High
Disease 110 96.72 Very High Very High Very High
Vomiting 22 96.12 Very High Very High Very High
Reprotox - General 2 44 95.12 Very High Very High Very High
Cardiovascular Disease 22 87.20 High High
Hypersensitivity 66 86.96 High High
Pulmonary Disease 22 84.04 Quite High
Adhesions 22 80.64 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
It should be noted that inhibition of PDE3 activity or an overexpression of a dominant-negative PDE3A construct has no effect on ?
Negative_regulation (inhibition) of PDE3
1) Confidence 0.34 Published 2008 Journal EMBO J Section Body Doc Link PMC2196435 Disease Relevance 0 Pain Relevance 0.08
A major aspect of this study was to examine the possible interaction between inhibitors of the PDE 3, PDE 4 or PDE 5 families.
Spec (possible) Negative_regulation (inhibitors) of PDE 3
2) Confidence 0.29 Published 2004 Journal Respir Res Section Body Doc Link PMC419478 Disease Relevance 0.45 Pain Relevance 0.19
To date, however, very little is known regarding the potential interaction between selective inhibitors of PDE 3, PDE 4 and PDE 5.
Negative_regulation (inhibitors) of PDE 3
3) Confidence 0.29 Published 2004 Journal Respir Res Section Body Doc Link PMC419478 Disease Relevance 0.45 Pain Relevance 0.15
Cilostazol, a PDE 3 inhibitor, is being used to treat circulatory problems [7].
Negative_regulation (inhibitor) of PDE 3
4) Confidence 0.29 Published 2004 Journal Respir Res Section Body Doc Link PMC419478 Disease Relevance 0.70 Pain Relevance 0.19
In passively sensitised human airways, allergen-induced contraction was inhibited only by the simultaneous inhibition of PDE 3 and PDE 4 and not by single inhibition of either family [25].
Negative_regulation (inhibition) of PDE 3
5) Confidence 0.29 Published 2004 Journal Respir Res Section Body Doc Link PMC419478 Disease Relevance 0.50 Pain Relevance 0.15
We therefore conclude that PDE3 inhibition by milrinone augments insulin secretion in vivo in mice after oral but not after intravenous glucose, which may be explained by enhanced response to the cAMP-dependent insulinotropic action of endogenously released GLP-1.
Negative_regulation (inhibition) of PDE3
6) Confidence 0.26 Published 2004 Journal Eur. J. Pharmacol. Section Abstract Doc Link 15364011 Disease Relevance 0 Pain Relevance 0
However, the PDE3 inhibitor augmented the insulin response to intravenous GLP-1 (2.8 nmol/kg).
Negative_regulation (inhibitor) of PDE3
7) Confidence 0.26 Published 2004 Journal Eur. J. Pharmacol. Section Abstract Doc Link 15364011 Disease Relevance 0 Pain Relevance 0
This may be due to a number of reasons such as alterations in PDE4 absorption across the gastrointestinal tract in the presence of PDE3 or PDE5 inhibitor or changes in intracellular signalling pathways.


Negative_regulation (inhibitor) of PDE3
8) Confidence 0.21 Published 2004 Journal Respir Res Section Body Doc Link PMC419478 Disease Relevance 0.61 Pain Relevance 0.20
Neither the PDE 3 inhibitor, cilostazol, nor the PDE 5 inhibitor, sildenafil, produced any significant anti-inflammatory effect.
Negative_regulation (inhibitor) of PDE 3 associated with inflammation
9) Confidence 0.21 Published 2004 Journal Respir Res Section Body Doc Link PMC419478 Disease Relevance 0.90 Pain Relevance 0.23
Our study used a combination of separate PDE 3 and PDE 4 inhibitor and not a dual/mixed compound which posses both PDE 3 and PDE 4 inhibitory potential.
Negative_regulation (inhibitor) of PDE 3
10) Confidence 0.21 Published 2004 Journal Respir Res Section Body Doc Link PMC419478 Disease Relevance 0.96 Pain Relevance 0.29
Examples of these are the PDE 3 inhibitor, cilostazol, for the treatment of intermittent claudication [7], and sildenafil, a PDE 5 inhibitor, for the treatment of sexual dysfunction [8].
Negative_regulation (inhibitor) of PDE 3 associated with reprotox - general 2 and restless leg syndrome
11) Confidence 0.21 Published 2004 Journal Respir Res Section Body Doc Link PMC419478 Disease Relevance 0.39 Pain Relevance 0.17
Members of both families are also expressed in cells of the immune system and considerable attention has been focussed on the potential of selective inhibitors of PDE 3 and PDE 4, or in combination, for the treatment of asthma and other inflammatory diseases [17-21].
Negative_regulation (inhibitors) of PDE 3 in immune system associated with asthma, inflammation and disease
12) Confidence 0.21 Published 2004 Journal Respir Res Section Body Doc Link PMC419478 Disease Relevance 0.75 Pain Relevance 0.23
This would not, however, be expected to occur with a single drug that contains combined inhibition of PDE 3 and 4.
Negative_regulation (inhibition) of PDE 3
13) Confidence 0.21 Published 2004 Journal Respir Res Section Body Doc Link PMC419478 Disease Relevance 0.60 Pain Relevance 0.14
The PDE 4 inhibitor, RO 20-1724, exhibited potent anti-inflammatory actions in vivo, whereas the PDE 3 inhibitor, cilostazol, and the PDE 5 inhibitor, sildenafil, did not.
Negative_regulation (inhibitor) of PDE 3 associated with inflammation
14) Confidence 0.21 Published 2004 Journal Respir Res Section Body Doc Link PMC419478 Disease Relevance 0.56 Pain Relevance 0.17
Any synergistic or additive effect between a PDE 4 inhibitor and an inhibitor of PDE 3 or PDE 5, may allow lower doses of drug to be administered and thus reduce the severity of any side effects.
Negative_regulation (inhibitor) of PDE 3
15) Confidence 0.21 Published 2004 Journal Respir Res Section Body Doc Link PMC419478 Disease Relevance 0.49 Pain Relevance 0.18
Interestingly, in an in vivo model of pulmonary resistance, the PDE 3 inhibitor, milrinone, and the PDE 5 inhibitor, zaprinast offer a synergistic effect when used in combination [27].
Negative_regulation (inhibitor) of PDE 3
16) Confidence 0.21 Published 2004 Journal Respir Res Section Body Doc Link PMC419478 Disease Relevance 0.41 Pain Relevance 0.14
These results suggest that concurrent treatment with a PDE 3 and/or PDE 5 inhibitor will reduce the anti-inflammatory effectiveness of a PDE 4 inhibitor.



Negative_regulation (inhibitor) of PDE 3 associated with inflammation
17) Confidence 0.21 Published 2004 Journal Respir Res Section Abstract Doc Link PMC419478 Disease Relevance 0.61 Pain Relevance 0.20
These results suggest that co-administration of a PDE 3 and/or PDE 5 inhibitor may reduce the anti-inflammatory effectiveness of a PDE 4 inhibitor.


Negative_regulation (inhibitor) of PDE 3 associated with inflammation
18) Confidence 0.21 Published 2004 Journal Respir Res Section Body Doc Link PMC419478 Disease Relevance 0.51 Pain Relevance 0.17
These findings are in agreement with the general consensus in that PDE 4 inhibitors are potent anti-inflammatory agents, whereas PDE 3 and PDE 5 inhibitors have little or no effect.
Negative_regulation (inhibitors) of PDE 3 associated with inflammation
19) Confidence 0.21 Published 2004 Journal Respir Res Section Body Doc Link PMC419478 Disease Relevance 0.50 Pain Relevance 0.23
is only completely inhibited by a combination of the PDE 3 inhibitor, motapizone, and the PDE 4 inhibitor, rolipram [24].
Negative_regulation (inhibitor) of PDE 3
20) Confidence 0.21 Published 2004 Journal Respir Res Section Body Doc Link PMC419478 Disease Relevance 0.58 Pain Relevance 0.18

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox